Montelukast

孟鲁司特钠

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameMontelukast
Drug Alias Name孟鲁斯特钠Romilast茂仑司特钠MontelukastumMontegen +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCysteinyl leukotriene receptor 1 antagonists
TargetsCysteinyl leukotriene receptor 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Exercise-induced bronchoconstrictionPersian Gulf Syndrome +[43] 
Global Approved IndicationsHypersensitivityRhinitis, Allergic, SeasonalRhinitis, Allergic, Perennial +[6] 
Approved Indications in ChinaHypersensitivityRhinitis, Allergic, SeasonalRhinitis, Allergic +[4] 
Original Approved Country/TerritoryMexico
Original Approved Date1997/07/31
Country/TerritoryCanadaUnited StatesVenezuela +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrganonAitiya (Shanghai) Pharmaceutical Co LtdMerck Sharp & Dohme Corp +[18] 
Inactive CompaniesInstitut Català De La SalutGenuine Research Center, EgyptThe Brigham and Women's Hospital +[22] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Exercise-induced bronchoconstrictionPersian Gulf Syndrome +[23] 
Inactive IndicationsIschemiaGraft vs Host DiseasePeripheral Vascular Diseases +[20] 

Other Information

ATC CodeR03DC03
Related LinksWikipediaDrugBankKEGG